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CHAPTER I
INTRODUCTION
Despite medical advances in the last several years, the incidence of cancer continues
to rise. Chemotherapy has long been used as a treatment for cancer. Cisplatin (cis-
diamminechloroplatinum II), an inorganic platinum compound has been used for over
twenty years as a chemotherapeutic treattnent for several types of solid tumors. It is used
primarily in the treaunent of lung, ovarian, and head and neck carcinomas (1).
Regardless of the benefits of chemotherapy, there are often many side effects.
Cisplatin is known to cause significant impairment in renal function resulting in the loss of
some trace minerals (1). Magnesium depletion secondary to cisplatin use has been
documented for many years (2). Research on cisplatin has indicated that it also may cause
increased renal excretion of zinc and copper (3). An increase in serum iron and ferritin
levels in patients receiving cisplatin has been noted in a few studies (4). The reason for
increased iron mobilization is unclear.
Selenium has been reported to decrease cisplatin's nephrotoxicity (5). No studies
were found regarding selenium status during treaunent with cisplatin. LillIe research has
been done on manganese status in the cancer patient. One study indicated a very slight
elevation of serum manganese concentration in a group of cancer patients versus a control
group (6). Generally, there appears Lo be no signiticant change in serum manganese levels
of the cancer patient.
Trace element levels appear to vary greatly from one individual to another
depending on health status and type of disease (7). The lack of knowledge regarding trace
element loss and supplementation in cisplatin patients supports the need for further research
2in this area The present study examined the effect of cisplatin chemotherapy on trace
element serum levels and urinary excretion.
The purpose of the study is to detennine the effect of cisplatin chemotherapy on
magnesium, zinc, copper, iron, selenium and manganese status in cancer patients.
The objectives of this study are as follows:
1. To detennine trace element (magnesium, zinc, copper, iron, selenium. and
manganese) concentrations in the serum of cisplatin patients at selected intervals
in their therapy cycle.
2. To detennine trace element (magnesium, zinc, iron. and manganese) urinary
excretion of cisplatin patients at selected intervals in their therapy cycle.
3. To detennine the creatinine clearance in cancer patients receiving cisplatin.
Hypotheses
The following hypotheses are postulated for this study:
HO1: There will be no significant effect of cisplatin chemotherapy on serum
magnesium, zinc, copper, iron, selenium, and manganese concentrations.
H02: There will be no significant effect of cisplatin chemotherapy on urinary excretion
of magnesium, zinc,iron, and manganese.
H03: There will be no significant effect of cisplatin chemotherapy on creatinine
clearance.
Definition of telTIlS
cisplatin -a water soluble inorganic platinum compound used as a chemotherapeutic drug
for treatment of solid tumors.
nephrotoxic - causing destruction to kidney cells.
hypomagnesemia - reduced magnesium concentration in the blood.
creatinine clearance - a measure of the kidney's ability to excrete nitrogenous waste
products.
glomerular flltration - the rate at which the kidney is able to flltrate water, small molecules
and protein out of the blood as it flows through the glomerulus; an important indicator of
renal function.
erythropoietin -hormone that stimulates the fonnation of red blood cells.
plasma - fluid portion of the blood in which microscopically visible fonned elements (red
blood cells, white blood cells and platelets are suspended).
serum - clear liquid that separates from blood when allowed to clot completely; blood
plasma from which fibrinogen has been removed.
This thesis was written in fonnat style according to Cancer journal specifications.
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4CHAPTER II
REVIEW OF TIffi LITERAlURE
Cisplatin
Cisplatin (cis-diamminedichloroplatinum IT) is an inorganic platinum compound that
has been used for many years in cancer chemotherapy. Cisplatin is effective when used
alone or in combination with other chemotherapeutic drugs for treatment of several types of
solid tumors. Cisplatin may be a curative treatment for early diagnosed testicular and
ovarian cancers. It is also used for palliative treatment in cancers of the head and neck.
bladder, prostate, lung, cervix and some pediatric cancers (l).
Cisplatin is a water soluble complex that contains a central platinum atom
surrounded by two chloride atoms and two ammonia moieties. Rosenberg et al (8) were
the first to show that cisplatin possessed antibiotic activity. The growth of Esch,richia
~ was inhibited by transforming the bacteria into long filamentous SlIuctures. Subsequent
studies by Rosenberg et al (9) demonstrated the antitumor activity of cisplatin in animaJs.
Cisplatin's mechanism of action apparently inhibit') DNA synthesis resulting in
inhibition of tumor growth. Antitumor activity is much greater when the chloride and
ammonia moieties are in the cis position permitting rapid and hifunctional DNA binding.
Studies using normal and cancerous tissue both in vitro (10) and in vivo (11) have
documented the mechanism of action for cisplatin. Exposure of these tissues to equivalent
therapeutic doses of cisplatin indicated a definite inhihition of new DNA synthesis. Little
or no concommitant effect on synthesis of RNA or proteins was found. Following these
and other studies, it became apparent that the primary target molecule of cisplatin in the cdl
is DNA. Antitumor action of cisplatin apparently occurs as a result of a reaction with the
5purine and/or pyrimidine bases of DNA (12). The base sites, however, have not been
clearly distinguished. There are several ways in which cisplatin could bind to the DNA
bases. It may bind to a single nucleophilic site (monofunctional binding) or it may bind to
two sites within a single DNA base or between two bases (bifunctional binding). Cisplatin
could cause intrastrand cross-linking where two bases are bound or cross linked by a single
platinum containing molecule on one DNA strand or it may bind to opposite DNA strands
known as interstrand crosslinking. Cisplatin could also fonn a crosslink: between DNA
and other molecules such as proteins (DNA-protein crosslink) (13). Recent evidence
suggests that the intrastrand crosslinking may be most important in cisplatin's cytotoxic
action (14).
In the most common mode of therapy, cisplatin is administered intravenously every
three to four weeks. Usual dosages range from 50-120 mg/m2 of body surface area.
Cisplatin is administered in a single dose or in divided doses over several days.
Cisplatin is diluted with physiologic saline immediately before infusion because it is
an unstable compound and may produce greater toxicity if diluted in solutions that do not
contain chloride ions (15). The chloride concentration is lower inside the cell. Chloride
groups are replaced by water molecules. This exchange creates a positively charged
compound which then may bind in more than one way as described above (14,16).
Once cisplatin is administered intravenously, it is rapidly distributed to nearly aU
organs, but begins to settle disproportionately in selected organs, particularly the liver and
kidney. Within ten minutes after administration to dogs, the amount of renal platinum was
three times that of plasma: 6.6 ~g1g vs 2.6 ~g1g respectively. Platinum was no longer
detectable 12 days later in the plasma but was still found in the kidney at a concentration of
approximately 0.6 ~glg (17). A study by Kaye and colleagues using a 14 C-Iabeled
cisplatin analog showed that the drug appeared to be most concentrated in the outer medulla
and inner cortex of the rat kidney (18). Choie and associates quantified the platinum in rat
kidneys 24 hours after a single intraperitoneal dose of 6 mglkg body weight. The
6renalcorticomedullary junction showed the greatest platinum concentration followed by the
renal cortex. Platinum was significantly higher in the cortex or corticomedullar junction
than in the remaining renal tissue (19).
Cisplatin apparently exists in three major compartments after intravenous infusion.
The three compartments include free or unbound. protein bound and erythrocyte bound
(20). Belt et al indicated a decrease in mean plasma platinum levels following
administration of cisplatin when given in combination with mannitol by rapid 15 minute
infusion. The initial value was 2700 nglml 15 minutes after infusion and fell to 200 nglml
2 hours post infusion (21). Zumkley and collegues disputed this finding by indicating an
increased concentration of platinum in the plasma by one hour after administration (less
than 0.0025 ~olesIL before therapy in 9 patients to 7.14 J.lmolesIL at one hour after
therapy in 7 patients). Twenty-four hours after cisplatin administration. platinum plasma
concentration was 9.08 ± 3.1 ~olesIL in 9 patients. Cisplatin plasma concentration then
dropped to 6.97 ± 1.27 J.lmoleslL 48 hours after therapy (3). Reasons why the plasma
level continued to rise until at least 24 hrs were not stated by the authors.
Urinary excretion of cisplatin in man and animals has been studied (22. 23. 24)
within 4-6 hours after cisplatin is administered. 27 to 70% is excreted in the urine.
Excretion depends on the time frame of administration (21). The mean fraction of the total
dose excreted is significantly greater (approximately 75%) after a 6 hour infusion versus 15
minute infusions (approximately 40%). This study also indicated that the use of mannitol
with cisplatin administration reduced the amount of cisplatin excreted in the urine in 24
hours (21). Following the rapid 15 minute infusions, the mean percent of cisplatin
excreted was 40%. Excretion was reduced to 18% in patients who were administered
mannitol with their cisplatin dose (21). After a 6 hour infusion of cisplatin without
mannitol, 75% of the dose was excreted within 24 hours. Patients who received mannitol
concomitantly in a 6 hour infusion cisplatin excreted only 22% in 24 hours (21).
However, Cvitkovic et al found total urinary recovery of cisplatin only slightly lower in
7mannitol treated dogs versus prehydrated animals (22). Belt and coworkers suggested that
differences could possibly be due to alterations in the binding behavior and reactivity of
various platinum species derived from cisplatin (15).
Zumkley et al studied 15 patients who received cisplatin in an 8 hour infusion
which revealed increased urine platinum excretion. A 24 hour urine was analyzed the day
before, the day of therapy and two days after cisplatin administration. Initial concentration
in 8 patients was less than 0.025 mg/24 hr before treattnent. This value rose to 34.65 ±
12.3 mg/24 hr the first day of treatment but dropped to 8.66 ±2.4 mg/24 hr the second day
after treatment (3).
Despite cisplatin's therapeutic effects, there are significant toxic side effects
associated with its use. These include impairment of renal function, hematologic
depression, high frequency hearing loss, anorexia, peripheral neuropathy, nausea and
vomiting. Nephrotoxicity of cisplatin has been documented pathologically and clinically
but the exact mechanism for the nephrotoxicity is unclear. Pathological evidence of
nephrotoxicity using renal tissue biopsies indicated that cisplatin may cause renal lesions
occurring in both the distal and proximal convoluted tubules and collecting ducts (25, 26).
Dentino et a1 (26) indicated that therapy with cisplatin resulted in a regular and persistent
decrease in the glomerular ftltration rate. Renal function was decreased approximately 40%
after only two courses of therapy. Apparently most patients who suffer renal impairment
never regain their pretreatment renal function (26).
The severity of renal impairment appears to be directly related over time to the total
dosage of cisplatin. Nephrotoxicity may increase with the combined use of cisplatin and
other nephrotoxic agents such as aminoglycosides (21) and with antihypertensive agents
(27). Electrolyte disturbances and trace mineral loss, including hypomagnesemia, occurred
in a significant number of cisplatin patients apparently as a result of renal tubular
dysfunction (25. 26).
Years of study have indicated that the incidence of nephrotoxicity may be greatly
8reduced by administering cisplatin with mannitol, saline or other diuretic agents. The dose
and length of cisplatin treatments can be varied to decrease nephrotoxicity (28).
Theoretically, the toxicity of cisplatin is reduced if the drug is given as a divided dose and
as a slow infusion (29). Pretreatment hydration appears to be the most important factor in
reducing nephrotoxicity (30). However even with aggressive hydration a reduction in
kidney function usually occurs. Aside from the nephrotoxicity, the major dose limiting
toxicities are anorexia and peripheral neuropathy (31).
Magnesium
Magnesium's importance in nutrition was fIrst documented by noting a defIciency
in rats and dogs in the 19305. In human nutrition, the imporlance of magnesium was noted
in 1934 in a few individuals with various disease processes. Healthy individuals rarely
experience a magnesium defIciency but those who suffer from clinical disorders may
become magnesium depleted (32).
The majority of the body's magnesium is found in the bone which contains
approximately 834-1200 mmol (approximately 20-28 grams) in a normal adult weighing 70
kgs. Approximately 27% is in the muscle, 6-7% in other cells and I % in extracellular
fluid. An estimated 7-10 mmol are found in the liver, heart and other soft tissues.
Magnesium is also found in the erythrocyte with normal magnesium content of about 2.2-
3.1 mmol/L. Magnesium content of the red cell depends on the age ot" the cell (magnesium
content drops with age) and on the analytical method used to measure its content. If atomic
absorption spectrophotometry is used, the usual range for adults, children and neonates is
about 0.70 - 0.75 mmoJJL. Magnesium in the erythrocyte and plasma is either complexed
with ions such as citrate or phosphate, protein bound or free (32). Plasma percentages of
magnesium are approximately 55% free, 13% complexed and 32% bound. Magne ium is
an important part of bone crystal and various cell membranes. Intracellular magnesium IS
approximately 6-10 mmollkg wet weight except for the erythrocyte which has less (32).
9Magnesium is a necessary ion in oxidative phosphorylation and essential to the
metabolism of ATP. Its primary function is to provide the structural stability of ATP.
Magnesium serves as a ligand for the ATP phosphate groups and is a part of some
transport systems (32, 33). It also takes part in processes such as glucose utilization,
contractibility of smooth and cardiac muscle, and synthesis of fat, muscle, protein and
nucleic acids. Magnesium is needed to facilitate over 300 different enzyme systems (32,
33).
The mechanism of magnesium absorption is controversial but there is agreement
that absorption efficiency is poor. The small intestine is the site where magnesium is
primarily absorbed, with more absorption in the jejenum than in the ileum (32, 34).
Magnesium absorption may involve two systems. One is a carrier-mediated system; the
other is simple diffusion (32). Studies have indicated a very wide range of absorption of
magnesium from food sources. Free living adults consuming self selected diets had an
average magnesium absorption of approximately 21% in males and 27% in females (35).
Other metabolic studies of magnesium intake in the usual diet showed average absorption to
be ~ 50-70% (32).
Once magnesium is absorbed, it may he retained for bone and tissue growth or used
as turnover replacement. Magnesium is stored in at least three different pools in the body.
One pool of extracellular magnesium provides quick turnover; another pool is mainly
intracellular magnesium and has slower turnover. One pool is skeletal magnesium which
has a very slow turnover rate (33). Magnesium that is not retained by the body is lost
through the kidneys. A large amount (approximately 80%) of serum magnesium is
ultrafIltrable and the proximal convoluted tubule resorbs 20-30%. The thick ascending
limb of the loop of Henle is the primary resorption site (50-65%). What is not needed is
excreted in the urine. Control of excretion of magnesium takes place between the thin
descending limb and early distal tubule (34). The concentration of magnesium in the
tubular lumen and in the plasma determines the amount of renal resorption in this area.
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The distal convoluted tubule and collecting tubules and ducts reabsorb very little (32).
Physiologic and metabolic conditions may affect how much magnesium is
reabsorbed in the nephron. A very important relationship exists between magnesium levels
and calcium. Magnesium deficiency decreases parathyroid hormone secretion which is
crucial in calcium homeostasis (36). It is possible that changes in serum magnesium may
influence how the body handles calcium and thus affect cell function (36.37). As
magnesium deficiency continues, parathyroid hormone output will decline until signs of
magnesium depletion are evident with symptoms such as hypocalcemia, hypocalcuria,
hypokalemia, sodium retention and others (38).
Disease processes that decrease intestinal absorption or impair renal function may
result in symptomatic magnesium deficiency (32). These would include malabsorption
syndromes, gastrointestinal and endocrine disorders, alcoholism, diabetes. protein energy
malnutrition, hypermetabolic states such as burns or trauma, prolonged low magnesium
diet ingestion and renal tubular dysfunction (32). Magnesium intake mayor may not have
a relationship with development of heart disease. cardiac arrhythmia and hypertension (39).
Certain drugs may influence magnesium absorption and utilization. Renal loss of
magnesium may be significant with the use of loop diuretics (furosemide and ethacrinic
acid) and nephrotoxic drugs such as cisplatin (32).
Hypomagnesemia which occurs as a result of cisplatin chemotherapy has been
documented by numerous studies over the past several years (2, 3, 40, 41). The basis for
this hypomagnesemia is the significant impairment in proximal tubular resorption and distal
tubular function caused by cisplatin chemotherapy (26, 27). Depletion varies with each
individual dose and with the number of doses given. In some patients. it appears that the
kidney may remain impaired for a number of days to months after therapy is completed (2,
3).
The severity of hypomagnesemia and its relationship to cumulative cisplatin doses
were first demonstrated by Lam et al (40). Patients were evaluated after each dose of a four
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cycle cisplatin chemotherapy regimen. Cisplatin dose and the relationship to low
magnesium were examined using linear regression analysis. Cumulative cisplatin dose (in
mg/m2) was used as an independent variable. Out of 28 patients, 10 had a low baseline
serum magnesiwn. Mean serum magnesium was 1.8 ±0.1 mg/dL before chemotherapy;
serum magnesium was 1.3 ± 0.1 mgldL after one cycle in 26 patients. Mter the founh
cycle (in eight patients), this value dropped to 0.9 ± 0.1 mgldL. Fourteen patients were
followed for an additional three to five month period after their last cycle. Ten continued
to have low serum magnesium during this followup period (2).
Plasma magnesium values may begin to fall as soon as three weeks after initiation
of chemotherapy (14, 41). Buckley and colleagues (2) treated 66 patients with 6 cycles of
monthly doses of cisplatin of 50 mg/m2 in combination with other chemotherapeutic drugs.
Hypomagnesemia developed in 41 % of these patients after a single course of therapy.
This increased to 100% after the patients had received six cycles of therapy. Serum
magnesium averaged 1.76 ± 0.27 mg/dL in 27 patients after one cycle of therapy and
continued to drop after each cycle to a final value of 1.20 ± 0.14 mgldL, in 12 patients after
six cycles of chemotherapy. The hypomagnesemia continued for an average of 4.5 months
in 104 (79%) of 136 determinations following cessation of chemotherapy. The mean
serum magnesium was 1.49 mgldL during this post therapy time period (normal was 2.4 ±
0.3 mgldL for this study). Average survival time was six months following cessation of
chemotherapy.
Since serum magnesium levels may not denote the actual cell content of magnesium
(42), a more accurate evaluation may be achieved by the study of magnesium concentration
of red blood cells during cisplatin therapy. Plasma magnesium (PMg) and erythrocyte
magnesium concentrations (EMg) were examined in twenty-two patients. These patients
received cisplatin ranging from 50 mg/m2 to I()()mg/m2. Samples were taken before
cisplatin therapy and at one, two, four and seven days after therapy (41). PMg decreased
from a basal value of 1.99 ± 0.18 mEqIL before therapy to 1.73 ± 0.25 mEq/L on the
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seventh day after therapy. EMg levels decreased after cisplatin administration from 4.11 ±
0.70 mEqIL before therapy to 3.55 ± 0.62 mEqIL on the fourth day after therapy. On the
seventh day after therapy, the EMg returned to pretreatment levels of 4.14 ± 0.70 mEqIL.
Urinary magnesium was measured in 14 of the 22 patients. Before cisplatin
infusion urinary magnesium was 6.51 ± 3.14 mEq/24 hr; it rose to 10.1 ± 3.45 mEq124
hr (p<O.OOl in comparison with day 0) one day after chemotherapy was given. Urinary
magnesium returned to a pretreatment level of 6.97 ± 2.71 mEq/24 hr on the second day
after therapy and rose to 7.91 ± 3.93 mEq/24 hr seven days after cispLatin was given (41).
Ten of these patients had PMg and EMg serial followups through six courses (6
months) of chemotherapy. Pretreatment EMg for these patients was 4.22 ± 0.34 mEqIL.
The EMg values were relatively unchanged after the first course of therapy at 4.34 ± 0.43
mEqIL and after the second course at 4.20 ± 0.40 mEqlL. Decreases were noted after the
third course of therapy with a value of 3.76 ±0.42 mEqIL (p<O.05) and following the
sixth cycle at 3.43 ±0.61 mEqIL (p<O.OOI vs time 0). The mean decrease in EMg from
pretreatment levels to final levels was 18.7% (p<O.OOl) (41).
During this six month period, PMg decreased after the tirst cycle from a
pretreatment mean value of 1.98 ±0.19 mEqIL to 1.89 ±0.24 mEq/L. There was a
statistical insignificant difference from the pretreatment levels to after the second course of
therapy with a value of 1.84 ± 0.17 mEqIL (p<O.05), becoming more evident after the third
course at 1.71 ± 0.19 mEqIL (p<O.OOl vs time 0). The value dropped after the sixth
course of therapy to 1.55 ± 0.2 mEq/L (p<O.OOI vs the third course). The mean decrease
after the sixth course of therapy was 21.7% when compared to pretreatment levels (41).
A marked decrease of plasma and red blood cell magnesium concentration levels
concurrent with the increase in plasma concentration levels of cisplatin has been observed
(3). Fifteen patients suffering from various malignant tumors were examined. An received
cisplatin (120 mg/m2) in an infusion lasting 8 hours. Magnesium concentrations in plasma
and red blood cells were evaluated before cisplatin therapy and at 1, 24, and 48 hours
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following cisplatin administration. Average plasma magnesium concentration before
therapy was 1.64 mmolesIL in 15 patients. Plasma magnesium levels was decreased to
1.45 ±0.18 mmoles/L 48 hours after therapy in 13 patients. Red blood cell magnesium
concentration before therapy was 4.88 ± 0.60 mmolesIL and was 4.73 ± 0.61 mmolesIL in
10 patients 48 hr after therapy was given (3). Urinary excretion of magnesium was
measured in the same study using 24 hour urine collection before. on the day of therapy
and two and three days after administration of cisplatin. Urinary magnesium concentration
before treatment was 81.6 ± 15.0 mg/24 hr in 15 patients. On the day of therapy this value
was to 168.9 ± 136.1 mg/24 hr and on the third day after treatment 50.7 ± 30.6 mg/24 hr
in 13 patients (3).
Results from these studies may suggest that cisplatin may affect magnesium
metabolism at the cellular level. Because cisplatin therapy causes injury to the transport
systems in which magnesium plays a stabilizing role. this injury may in turn cause an early
shift of magnesium from cells into the bloodstream. Magnesium may then be taken up
from the plasma during the repair process in order to recover the normal cellular content
(41).
The incidence and severity of nephrotoxicity reactions and hypomagnesemia were
reduced when patients receive intravenous mannitol and 0.45% saline during and after
cisplatin administration (43). Hypomagnesemia may also be decreased when doses are
more widely spaced and with the avoidance of rapid infusion rates (2).
Magnesium supplementation is often given before and during cisplatin infusion.
Few studies have been done to determine the benetit of oral supplementation. Because the
red blood cell concentration of magnesium did not decrease until after the third cycle of
chemotherapy in the study by Sartori and coworkers. it is presumed that actual depletion of
magnesium may not occur until1ater in the treaunent cycle. It is possible that oral
magnesium supplements should therefore be given later in the treatment course and
between cycles of chemotherapy for maximum benefit and to avoid the risk of
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hypennagnesemia (41). Further studies are needed to defme optimal protocols for oral
magnesium supplementation during cisplatin chemotherapy.
Zinc
The discovery of the nutrient role for zinc stems from research indicating its
importance in plant life almost one hundred years ago (44. 45). The essentiality of zinc for
animals was first reported in 1934 (46). Human zinc deficiency was first documented
clearly in the early 1960s (46). This discovery was based on the finding that growth
depression and delayed sexual development occurred in young Iranian and Egyptian men
who had consumed vegetable protein based diets which were low in zinc (44. 48).
Symptoms resolved after they were given zinc supplements (47).
Zinc is present in all cells but some tissues have a higher concentration than others
(43). The human body zinc content is approximately 1.5 - 3 grams (44,47). Most zinc is
found in muscle, bone, liver and skin. Bone, prostate, and the choroid of the eye have the
highest concentration of zinc (44). A substantial portion (60%) of total body zinc is found
in skeletal muscle because it makes up the greatest portion of total hody mass. Skeletal
ml!lSCle and bone account for approximately 90% of all zinc found in the human oody (45,
47).
Dietary intake of zinc may be reflected in the concentration of zinc in some tissues
such as bone, testes, hair, blood, intestine and liver. Other tissues such as brain, lung,
heart. erythrocytes and muscle contain stahle levels of zinc and are not readily affected by
dietary intake (44, 47).
Red blood cells contain 75-80% of the blood zinc stores. Plasma contains 12-22%
and the remaining zinc is found in leukocytes and platelets (44,45). Even though less than
0.5% of total body zinc is found in blood, plasma zinc is commonly used to estimate whole
body zinc status (45).
Zinc is not accumulated and stored in the hody. However, even though the large
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amounts of zinc found the bone and muscle are not easily assessible, there are small pools
of zinc in the bone, plasma. and liver that are able to exchange zinc rapidly when needed
(49, SO).
Zinc plays a major role in many structural, catalytic, and regulatory functions of
human metabolism (44,47). Zinc is crucial in the functioning and structure of more than
60 enzymes (44). Zinc also plays a major role in the processes of cell replication and
protein and nucleic acid metabolism (44).
The method by which zinc is transported across the intestinal mucosa is unclear.
Both a carrier-mediated process and simple diffusion may be involved (44, 49).
Circulating zinc in the blood is bound to albumin, transferrin, alpha- 2- macroglobulin and
amino acids (49). The liver, which is the main organ involved in zinc metabolism,
exchanges 30-40% of zinc in the portal blood (44).
The actual mechanism of absorption of zinc is unclear. It is absorbed throughout
the small intestine but it is not clear which segment has the highest absorption capacity
(49). Zinc absorption efficiency increases during dietary deficiency and decreases when
intake is high (44, 47, 49).
Gastrointestinal absorption and gastrointestinal excretion of zinc are the primary
ways that homeostasis is maintained. Healthy individuals excrete little zinc in the urine
(49). Most zinc is lost through the feces and is a reflection of how much zinc is
unabsorbed from the diet as well as endogenous zinc (44, 49). Trauma, severe burns.
major surgery or a "stress" that is severe enough to cause muscle catabolism may increase
urinary zinc loss (49).
Even though overt zinc deficiency is relatively rare (44), a deficiency would have an
effect on numerous organ systems within the body; rapidly dividing tissues would be most
susceptible to zinc deficiency (49). Enzymes dependent on zinc also are involved in
collagen synthesis for wound healing. In addition, zinc also affects some immunological
proteins such as thymulin (49).
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Zinc interacts with a number of different honnones. In experimental animals and
humans, a deficiency of zinc has been linked with impaired glucose tolerance (44, 49)
suggesting involvement with insulin. Zinc also interacts with other hormones including
growth hormone, gonadotropins, sex honnones, thyroid honnones and conicosteroids.
These hormones may also alter zinc metabolism (44, 49).
There are a variety of physical and environmental factors which influence zinc
status. Disease can affect zinc intake, absorption and excretion. Disea...;;es involving
mucosal damage and malabsorption syndromes may impair zinc absorption. Some
diseases such as diabetes, sickle cell anemia, muscular dystrophy and chronic infections
may result in increased zinc excretion. Anorexia causes increased urinary zinc loss
secondary to increased muscle catabolism. Skin conditions Stich as dandruff and psoriasis
may cause zinc loss. Malignant cells demand zinc for growth in many types of cancers;
this increases the body's need for zinc (49). Hypennetabolic situations such as surgery or
severe bums will alter zinc metabolism by increasing blood zinc levels and subsequently
increasing urine losses. Prolonged hospitalization, use of some medications,
gastrointestinal dysfunction, renal disease and excessive alcohol use can lead to zinc
depletion and increase zinc needs (49). Symptoms of zinc deficiency may differ due to its
various roles in metabolism. Symptoms may be nonspecific and include loss of appetite.
dermatitis, reduced taste acuity and decreased immune function (49).
A minimal amount of research has been done on cisplatin's effect on zinc status.
The actual renal processing of zinc is not well understood and zinc status rarely is measured
in routine clinical lab assessments (49). However, some evidence indicates that the use of
cisplatin as a chemotherapeutic drug may cause zinc depletion. A study using animals
reported that cisplatin does lower hepatic zinc concentrations (52). In a short term study,
Zumkley et al (3) found increased urinary zinc excretion following cisplatin rherapy in a
small number of human participants. This study analyzed renal loss of zinc the day before,
the day of treatment and two and three days after treatment. Due to the large fluid supply of
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forced diuresis, all patients had increased urine volumes. Zinc loss was elevated one day
after treatment (in five patients) from 0.412 ±0.278 mg/24 hr before chemotherapy
treatment to 1.27 ± 1.05 mg/24 hr one day after treatrnenl Followup study on the second
day indicated urinary zinc was 0.634 ± 0.296 mg/24 he in five patients but decreased to
0.380 ± 0.258 mg/24 hr on the third day in 3 patients (3).
Plasma concentrations of zinc were also measured in the Zumkley study (3).
Samples were taken before therapy and at selected hourly intervals following therapy.
Plasma concentration of zinc before therapy was 10.75 ± 2.92 ~oVL in 9 patients.
Levels were 11.11 ± 0.88 IlmollL at 1hour following therapy. Following therapy 24 hrs
later, the concentration was 12.68 ± 3.8llmollL and 13.35 ± 5.4llmoVL 48 hours after the
dose was given.
Zinc concentration in the red blood cells in this study was measured on a number of
patients before therapy was begun and again at one, twenty-four and forty-eight hours after
administration of cisplatin. Initial zinc concentration in the red blood cells of nine patients
was 10.75 ± 2.92 IlmoleslL. This value increased to 13.34 ± 5.4 ).1molesiL 48 hours after
treatment. Five patients were used to detennine the final value (3).
Zumkley et al suggested three possible reasons for these alterations: the intluence
of the forced increased fluid load (that is commonly prescribed with cisplatin therapy), the
negative effect of cisplatin on renal ability to preserve trace elemenLli and the general role of
renal dysfunction (3).
Sweeneyet al (51) studied cisplatin therapy and and il') role in zinc depletion.
Using patients with biopsy confmned squamous cell carcinoma, a twenty-four urine
collection was completed and fasting blood samples were drawn for analysis. All patient')
in this study received cisplatin at a dose of 100 mg/m2 over a 2 hour period or in a dose of
20 mg/m2 daily for 5 days as a continuous infusion. Five patient') receiving this therapy
were assessed for the effect of day to day and diurnal variation on plasma zinc samples
drawn at 7 a.m., 3 p.m., 6 p.m., and J0 p.m. Diurna~ variation in plasma zinc was evident
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in that the higher levels were fasting concentrations in the morning. These ranged from
approximately 0.85 to 1.10 llg!mL at 7 a.m. fasting to 0.51 to 0.90 llg!mL at 3 p.m.; 0.6
to 0.9 llg/mL at 6 p.m. with a final reading of 0.61 to 0.90 IlglmL at 10 p.m. Urinary zinc
variation between individuals was greater than variation within the individual.
Day to day variations in urinary excretion of zinc were studied on urine collected on
two or three occasions over a one week period following cisplatin therapy. Fifteen patienl"
were studied. Values rose from 600 1lg/24 hr before cisplatin to approximately 900 IJgl24
hr following cisplatin therapy (51).
The effect of cisplatin on plasma zinc was also assessed on these fifteen patients.
Mean plasma zinc was 0.851lg/mL before therapy and dropped to 0.70 IlglmL 5 days after
chemotherapy. Statistical analysis using a paired t test indicated that the decrease in plasma
zinc was significant (p< 0.05) (51). The increase in the urinary zinc did not reach
significance due to small sample size and a large standard deviation (51). However, this
study established a defmite trend toward hypozincemia and hyperzincllria (5 l). The results
did not indicate how cisplatin may have increased zinc excretion in the urine. Urine volume
and zinc excretion were not related. The researchers hypothesized that cisplatin increased
the excretion of amino acids such as histidine and cysteine (40) which has heen shown to
increase urinary zinc excretion (53).
Zinc loss may be important clinically in the cancer patient for many reasons. Some
believe that zinc depletion may deprive the tumor of essemial nutrienl'i resulting in a hendit
to the host (54). On the other hand, zinc depletion could weaken the immune system and
encourage tumor growth (55). Hypogeusia is a side effect experienced by many cancer
patients given cisplatin. Hypogeusia is sometimes a symptom of zinc deficiency (56).
Because past studies indicate that cisp)atin may resul t in zi nc deficiency, this
possibility should be taken into consideration for patients receiving cisplatin therapy.
Further studies need to be done to determine whether or not zinc supplements would be
beneficial in the care of the cisplatin patient.
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Copper
Copper was first recognized as necessary to cure iron deficiency anemia in rats fed
a milk diet in 1900 (57). Work that clearly established the importance of copper for the
fonnation of hemoglobin was reviewed in 1979 (58). The activities of certain
metalloenzymes are dependent on copper and copper deprivation results in decreased
activities of these enzymes (59). The study of Menke's disease. a genetic disease that
occurs from a defect in copper metabolism and absorption. has dearly demonstrated the
importance of copper in human nutrition (60).
The adult human body contains approximately 80 mg of copper with the highest
tissue concentration found in the liver which contains approximately 15%. Approximately
10% is found in the brain with muscle content at 40% of the total amount (57. 58). Copper
is stored in the liver and spleen. Most of the copper in the liver cells is found in the cytosol
(57).
Ceruloplasmin supplies copper to other tissues to aid in the formation of
cuproenzymes such as cytochrome c oxidase, superoxide dismutase and lysyl oxidase (61).
The mechanism by which ceruloplasmin copper is made available to the cell is unclear. Il
may enter the cell intact or the ceruloplasmin copper may be transferred to an intracellular
protein after it has been reduced to Cu+ (59).
Copper is absorbed in all areas of the gastrointestinal tract including the stomach
and large intestines. The duodenum appears to he a major ahsorptive site. Absorption is
regulated at the intestinal mucosa level (60). Newly ahsorbed copper is transported from
the small intestine and is loosely bound to alhumin and some free amino acids. Most of
this copper is incorporated into ceruloplasmin after it is taken up by the liver. The
ceruloplasmin is released into the hlood where it makes up approximately 90% of the
plasma copper pool (57).
Copper bioavailability may be affected by dietary factors. Of most importance is
the adverse effect of zinc on the availability of copper. High amounts of dietary zinc may
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intensify the symptoms of decreased copper status (61, 62). Generally. copper deficiency
in humans is rare but has been noted in individuals taking amounts ranging from 50 mg to
150 mg of zinc per day (63). High dietary ascorbic acid also reduces the bioavailability of
copper by affecting not only intestinal absorption but also its utilization (64). Most copper
is excreted through the gastrointestinal tract. Only a small amount (less than 3%) is found
in urine. Bile is the major contributor of endogenous fecal copper (58).
Copper deficiency may result in reduced activity of several cuproenzymes.
Vascular disease, rupture of major vessels. and osteoporosis may develop as a result of
decreased lysyl oxidase activity (65). Without adequate copper, the crosslinking in
collagen and elastin is reduced which can result in spontaneous rupture of major hlood
vessels. Melanin formation is compromised when tyrosinase activity is decreased; copper
deficiency also decreases cytochrome c oxidase activity which is needed for electron
transport (65).
Dietary copper is imponant in the function of superoxide dismutase (SOD), an
important enzyme in free radical defense. Copper deficiency may lead to reduced SOD
activity in liver, lungs and erythrocytes (66). Adequate amounLS of copper also may help
prevent anemia. Presumably this anemia may be due to decr~ed SOD activity which
causes increased free radical accumulation resulting in changes in the plasma membrane
(67). This process ultimately may shorten the survival time of red blood cells (59).
Adequacy of copper affecLS iron metabolism. Studies in mice have indicated that
the amount of dietary iron present and the sex of the animal directly affect the hematologic
response to copper deficiency (68). The specific role for copper in anemia prevention and
iron mobilization is unclear (59). Copper deficiency also may cause hypertrophy of the
heart. Rats that were copper deficient showed cardiac enlargement as well as ventricular
aneurysms. Copper deficient heans contained less norepinephrines which may relate to
cardiac malfunction. Electrocardiograms done on raLS showed the occurrence of bundle-
branch block and nonspecific alterations of patterns sometimes seen with metaholic
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imbalance (61). Humans consuming low amounts of dietary copper also have exhibited
abnormal electrocardiographs (69).
Other effects of copper deficiency include its relationship to brain catecholamine
pool size (70) and the possibility that copper deficiency causes an increase in lipid
peroxidation of cell membranes (57). In copper-deficient mice (depending on the degree of
deficiency), a decrease in natural killer cell cytotoxicity and helper T cells was found.
Immune system competence was restored with copper therapy (71).
Studies have indicated that cisplatin therapy may cause an increased renal excretion
of copper and may result in copper depletion. Zumkley et al (3) studied copper
concentration of plasma and 24 hour urine collections before and during cisplatin therapy.
Copper status using 24 hour urine excretion as a measure was examined on the day of
therapy and two and three days after cisplatin was given. Renal excretion of copper the
first day after therapy was 0.026 ±0.015 mg/hr before treannent in eight patients and
0.119 ± 0.041 mglhr after the first day of treatment. Urinary copper on subsequent days
decreased from 0.060 ± 0.018 mg/hr after the second day of treatment in eight patients to
0.029 ± 0.021 mglhr after the third day of treatment measured in three of this group of
patients (3).
Little change was noted in plasma copper concentrations hefore therapy, one hour,
24 hours, or 48 hours after cisplatin administration. Initial values were 21.0 ± 532
IlmolesIL before therapy was begun and 21.87 ± 3.24llmoleslL f(my-~ighthours after
therapy. The reason for the alteration in trace mineral metabolism during cisplatin therapy
in this study may be related to the specific effect cisplatin has on the renal excretion of trace
minerals (72).
Another series of studies using samples of rat kidney tissue suggested that loss of
kidney copper was due to impaired resorption secondary to cisplatin administration (73).
DeWoskin and Riviere evaluated kidney tissue biopsies and indicated that although cisplatin
therapy did not produce an immediate drop in kidney copper, by the fourth day after
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cisplatin treaunent, there was a 71 % reduction in kidney copper (73). Further study is
needed to define toxicity and kidney copper loss resulting from cisplarin chemotherapy.
Iron
The study of iron nutrition began as early as the 18th century (74). Use of iron
supplements began in 1832 and iron deficiency in infants was first noted in 1892. The fact
that iron deficiency can be prevented and that it is the most common nutritional deficiency
in the United States has been clearly documented (75).
Iron is found most abundantly in the human body in hemoglobin in the
erythrocyte and is bound to transferrin in the plasma. Hemoglobin transports oxygen from
the lungs to tissues and makes up more than 95% of the red cell protein. More than 10% of
whole blood weight is made up of hemoglobin (75).
Hemoglobin is made up of a complex of globins and heme proteins (proteins with
an iron-porphyrin prosthetic group). This allows iron to stabilize in the ferrous state so that
it may function as an oxygen carrier. Hemoglobin is the most abundant of the heme
proteins and makes up >65% of body iron. Hemoglobin synthesis takes place in the final
stages of red cell development in the bone marrow (76).
Blood levels of hemoglobin vary among individuals depending on age, sex,
nutrition. pregnancy. altitude and disease. Increased levels of hemoglobin in males occur
at puberty and continue to rise with age. The highest hemoglobin level for females occurs
after menopause or hysterectomy when blood is no longer lost through menses (77). Men
average approximately 3.8 grams of total body iron and females average 2.3 grams (78).
The protein myoglobin which transports and stores oxygen for use in muscle contraction
accounts for approximately 10% of total body iron (75, 78).
Storage iron in the body occurs mainly in the compounds ferritin and hemosiderin.
These compounds are found in highest concentrations in the liver, spleen, and bone
marrow (76, 80). Iron deficiency anemia will not develop until these iron stores are
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almost total1y depleted.
Iron is delivered to the tissues by plasma transferrin. Transferrin specific cell
membrane receptors bind with the transferrin- iron complex and carry it into the cell where
the iron is released (79). Some tissues such as placenta, liver and erythroid precursors
contain large numbers of transferrin receptors so uptake of iron in these tissues is quite
high (82).
Absorption takes place throughout the small intestines, and absorption is mos't
efficient in the duodenum. This absorption also involves the cell receptors specific for
transferrin. During periods of need, iron is more readily absorbed by these receptors (79).
The number of receptors decrease when stores are adequate (74).
Absorption of iron is affected by iron stores in the body as well as by age,
condition of the gastrointestinal tract and state of health of the individual. The amount and
chemical state (heme versus nonheme) of dietary iron ingested and other dietary
components also influence absorption (74). Absorption of iron from food varies from less
than 1% to greater than 50%, depending on the individual's physiological need for iron,
food source and composition of the diet. (78)
Iron is lost mainly in the feces from desquamated mucosal cells and from the loss of
minute amounts of blood (80). Little iron is lost through the urine. Females lose more iron
than males during childbearing years through menstruation.
Food contains two types of iron. Heme iron is found only in animal products; non
heme iron is found in both animal and plant products. Greater than 85% of iron in the diet
is non heme. Non heme iron is not absorbed as well as heme iron, and the amount of
absorption depends on whole meal composition. If heme sources of iron such as meat,
fish or chicken are eaten in combination with non heme iron sources, iron absorption will
be approximately four times greater than if no hemo iron were consumed at that meal (81).
Iron deficiency is a nutritional problem in the United States and world-wide,
possibly because the iron in the most common foods such as cereals and legumes is poorly
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absorbed (82). Iron depletion usually progresses slowly and occurs in three stages. The
first stage does not result in any physiological changes. It is characterized by "low iron
stores" and may be measured by a decrease in serum ferritin.
Biochemical changes may indicate the second stage of depletion. In this stage, the
depletion is severe enough to decrease the normal production of hemoglobin and other iron
compounds. This stage can be detected by a decrease in transferrin saturation and an
increase in erythrocyte protoporphyrin. In this stage, the hemoglobin level has not yet
fallen to the level considered to be true anemia.
The third stage is actual iron deficiency anemia. Hemoglobin production has been
suppressed to the point that the hemoglobin concentration is below the normal range of
health for an individual. Iron deficiency anemia is diagnosed if it is accompanied by other
lab values which are also abnormal such as a low serum ferritin (83).
Iron deficiency anemia is usually caused by decreased absorption of dietary iron,
rapid growth or blood loss (85). Indications of iron deficiency anemia vary with the degree
of depletion. Studies have shown that anemia may cause a decrease in work capacity (86).
Some human studies have shown even mild anemia may compromise exercise performance
(84). Other symptoms of iron deficiency anemia include the inability to maintain body
temperature in a cold environment (85) and decreased resistence to infection (86).
Since early symptoms of iron deficiency anemia are so subtle, the deficiency is
usually fust suspected following a low hemoglobin or hematocrit and/or a history of low
dietary iron intake. If a low mean corpuscular volume (MCV) and mean corpuscular
hemoglobin (MCH) are found, then there is a strong possibility that the diagnosis is iron
deficiency anemia. Additional lab tests such as erythrocyte protoporphyrin, serum ferritin
and transferrin saturation may be used to confmn a diagnosis of iron deficiency anemia
(83).
Changes in serum iron status following cisplatin chemotherapy have been noted in
only a few studies (87). These studies have indicated that cisplatin does affect iron
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metabolism. Grau et al (4) were the first to note an increase in plasma iron levels following
cisplatin chemotherapy. Twenty patients with stage III lung cancer receiving doses of 120
mg 1m2 of cisplatin were studied. Plasma iron levels were obtained before treatment was
begun and again after two courses of cisplatin given at 3 week intervals. Plasma iron
concentrations were found to be elevated in fourteen out of twenty patients. The mean
initial value was 66.50 ±29.74 JlgldL. This rose to a value of 127.55 ±71.47 JlgldL
which was a significant increase (p<O.OOl). Plasma iron levels in these patients returned to
baseline several months after cessation of cisplatin therapy. Authors of this study
concluded that hydration measures and other concomitant drugs given with this therapy
were not relevant in this outcome (4).
The effect of cisplatin chemotherapy on iron and unsaturated iron binding capacity
(uIBC) was studied in children (87). Records of nine patients from 1984 to 1986 were
reviewed. Cisplatin was given at a dose of90 mg/m2. These patients received 3 to 9 doses
of chemotherapy at 3-4 week intervals. The average serum iron level before therapy was
75.7 ± 30.6 Ilg/ml. This level rose to 162.0 ± 65.3 Jlg/ml one day after the first course of
cisplatin. The uIBC initially was 181.9 ±33.0 Jlg/ml and then dropped to 86.4 ±44.6
Jlglml after one cispiatin treatment.
Iron and uIBC levels were reviewed before and after the subsequent three doses of
cisplatin. A significant decrease in uIBC and an increase in serum iron were noted within
twenty-four hours after each cisplalin administration. A cumulative effect was seen in the
elevation of iron (150 Ilg/ml before the fourth treatment of cisplatin to approximately 210
Jlglml after the fourth treatment of cisplatin). There was a decrease in the ulBC
(approximately 210 Jlglml before the fourth treatment to approximately 65 Jlglml) after the
fourth cisplatin treatment. This clearly indicated cisplatin's effect on iron metabolism.
Two to four months after therapy was completed, iron and uIBC returned to baseline levels
(87). Since over 90% of cisplatin is hound to proteins in the plasma (88), KIetter et al
theorized that the serum iron increase may be the result of the competitive displacement of
26
iron from plasma proteins which increases the serum level and thus decreases the "free"
binding sites (87).
The relationship between cisplatin and impaired erythropoiesis in patients receiving
cisplatin was studied (89). Patients were divided into three groups. One group (Group A)
of fourteen patients received a total of 30 courses of very high dose chemotherapy 40
mg/m2 per day for five days in 3% hypertonic saline together with a 120 hour continuous
hydration). Group B included 5 patients each of whom received 2 to 4 courses of cisplatin,
20 mg/m2 per day for 5 days with one hour hydration in combination with other
chemotherapeutic drugs. Group C consisted of twelve patients receiving 1 to 3 courses of
cisplatin, 100 mg/m2 on day 1 with 4 hour hydration followed by 5-fluorouracil
Igrn/m2/day as a 120 hour continuous infusion.
Serum iron, ferritin, and hemoglobin concentrations were evaluated before and four
and six days after each course of cisplatin. In group A, serum iron increased significantly
from pretreatment levels of68.3 ± 31.81lg/dl to 185.3 ±67.8 by day 4 (p<O.Ol) after
cisplatin administration. On day 6 levels were 191.6 ±91.5 j.1g/dl (p<OJ)() 1). Ferritin
levels in Group A rose from a pretreatment value of 166.5 ± 251.1 Ilg/dlto 335.8 ± 303.1
J.1g/dl on day 4 (p<O.Ol) and to 520.7 ± 392.7 Ilg/dl (p<O.OOl) on day 6.
Group B also showed an increase in serum iron from a pretreatment value of 99.2
± 23.9 to 184.8 ± 69.8 J.1g/dl on day 4 (p<O.OOl) and 161.6 ± 65.4 J.1g/dl (p<O.Ol) on day
6. Serum ferritin concentration also rose significantly from 158.2 ± 160.3 J.1g/dl to 301.1 ±
185.4 J.lg/dl (p<0.05) on day 4 and 408.6 ± 379.0 Ilgld1 (p<O.05) on day 6. In group C,
serum iron rose from 102.9 ± 37.3 J.lgldl to 211.9 ± 66.1 J.1g1dl (p<O.cXH) on day 4 and to
165.7 ± 64.4 j.1g/dl (p<O.OOI) on day 6. Ferritin levels rose from 312.0 ± 340.0 J.1g/dl to
471.2 ± 360.2 J.lg/dl (p<O.05) on day 4 to 491.1 ± 334.0 J.1g/dl (p<O.01) on day 6.
A decrease in the hemoglobin value was also noted in all three groups after only the
first course of cisplatin. Group A indicated a 15% hemoglobin fall after the first course of
chemotherapy. The lowest mean value was 10.5 ± 2.2 gldl observed 17.6 ± 3.1 days after
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beginning therapy. Hemoglobin concentrations in Group B fell 9% after the first course of
therapy with a low mean value of 12.4 ± 1.5 gldl, 18.2 ±3.8 days from the beginning of
the rust course of therapy. An 11% decrease in hemoglobin was noted in group C after the
first course of therapy 16.8 ± 4.9 days after starting the first course of chemotherapy. In
27.6% of all courses in group C, a fall in the hemoglobin of greater than 2 gldl occurred.
Pollera et al concluded that iron status depends on chemotherapeutic dose but is not
related to different schedules. The severity of anemia was determined by the cisplatin dose
given as well as the hemoglobin pretreatment levels (89).
A previous study by Pollera et al also indicated significant changes in serum iron
and ferritin levels following one treatment of cisplatin (92). Eighteen patients receiving 40
mglm2 per day for 5 days every 4-5 weeks were studied. Blood samples were drawn for
analysis at three different times: the morning before the first drug administration, on the 7th
day and 4 weeks from the start oftherapy. Serum iron concentration rose progressively
during the first four days of cisp.Jatin therapy and reached a peak on day 5 of therapy. In
many patients, the serum iron concentration doubled after only 24 hours. These
concentrations then decreased to pretreatment levels during the second week after initiation
of therapy. Serum ferritin levels began to rise on the second or third day of therapy and
reached the highest point on the 7th or 8th day. The levels then returned to baseline after a
two week time period. Two way analysis of variance on the first ten days after initiation of
therapy indicated these changes were significant (p<O.OOl) for both iron and ferritin. The
average hemoglobin concentration was increased on day 7 after treatment was fmished and
also returned to baseline within the second week after the start of therapy. The significant
increase of serum iron and its rapid fall after discontinuation of therapy would indicate a
direct effect of cisplatin on iron (90). Because the same patterns of changes in iron and
ferritin were noted in all groups, the cisplatin therapy was considered to he directly
responsible (89, 90).
There are several theories on the mechanism of cisplatin-induced iron mobilization.
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Increased iron mobilization would increase serum iron and affect ferritin values. Concepts
such as an erythropoietin deficiency syndrome secondary to nephrotoxicity of cisplatin
(91), possible inhibition of erythropoesis by cisplatin (92) and the competitive displacement
of iron from proteins in the plasma (87) have been suggested. Further studies are needed
to clarify the mechanism by which cisplatin affects iron status.
Selenium
A requirement for selenium in human nutrition was not observed until 1979 when
an association between selenium and a cardiomyopathic disease in young children was
established in China (93). A simultaneous deficiency of selenium and vitamin E causes
many symptoms which can be prevented or cured by supplementation with either nutrient
(93). Selenium deficiency in living animals with adequate vitamin E intake has been
observed only under experimental conditions. An absolute selenium deficiency was seen in
rats which were fed a low selenium diet adequate in vitamin E. This resulted in poor
growth, cataracts, and reproductive failure (94). Chicks fed diets severely deficient in
selenium suffered from nutritional pancreatic atrophy (95).
Selenium is found in the red blood cell in two different compartments or forms. In
glutathione peroxidase and selenoprotein P (a selenium transport protein in some animals),
it is found as selenocysteine. The other fonn is selenomethionine which is derived from
the diet and is not synthesized by the body. Selenomethionine is not regulated by the
selenium status of the animal; it is considered to be an "unregulated" storage compartment.
It may be incorporated into proteins in the place of the amino acid methionine (96). The
selenomethionine pool provides selenium to the individual should the dietary supply
become depleted (97).
The selenocysteine compartment is regulated and is responsible for the biological
activity of selenium. Selenocysteine is synthesized and inserted into proteins by a specific
mechanism which is still under investigation. Excess selenium is excreted if it is not
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needed for selenocysteine formation. There may be other fonns of tissue selenium that
have not yet been identified (96).
Selenium functions as an antioxidant Hydrogen peroxide and other free radicals
are removed by glutathione peroxidase, a selenoenzyme present in cells and in plasma (98).
Fatty acid hydroperoxides present in phospholipids are metabolized by the selenium
containing phospholipid hydroperoxide glutathione peroxidase (99). Selenium may also
have additional antioxidant effects (100).
Absorption of organic and inorganic selenium appears to be greater than 50%.
Selenornethionine is processed metabolically the same as methionine (96). It is inserted
into proteins in place of methionine and becomes a part of the tissue selenium. The
selenium in selenomethionine is not released until the selenomethionine is broken down
freeing selenium for use for specific activities (96). Methionine intake determines the rate
of selenomethionine catabolism (101). A low methionine intake may result in a selenium
deficiency which would cause decreased glutathione peroxidase activity. Because dietary
selenomethionine is sequestered in protein, decreased glutathione peroxidase activity may
occur despite adequate selenium intake. High methionine intake leads LO catabolism of
methionine and selenomethione resulting in release of selenium and repletion of the
selenium deficiency (102).
Selenocysteine is formed when selenium is incorporated into serine in place of
oxygen. It is then combined with a selenoprotein such as glutathione peroxidase (103).
The enzyme selenocysteine B-Iyase is presumed responsible for the catabolism of
selenocysteine as well as the release of selenium from dietary selenocysteine (104).
Selenium is excreted through the urine (96).
Selenium influences many biochemical activities. The activities of drug
metabolizing enzymes may be affected by a selenium deficiency (104). Selenium
deficiency studies in the rat indicate that selenium deticiency may lead to increased hepatic
glutathione synthesis. increased hepatic heme turnover and changes in the utilization of
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glucose (105).
Several diseases have been linked to selenium deficiency. Keshan disease. a
cardiomyopathy affecting women and children in China. is controlled by selenium
supplementation (106). Low selenium status may also be associated with a type of
osteoarthritis, Kashin-Beck disease.
Selenium concentration in fluids and tissues may be measured in a number of ways
including fluorometry, neutron activation analysis. atomic absorption and mass
spectrometry (96). Measurement of glutathione peroxidase activity (107) and selenoprotein
P (110) concentration may be used to estimate the biologically active selenium.
The metabolism of selenium must be understood in calculation of selenium
concentration. Because selenomethione is substituted for methionine in some proteins,
intake of this fonn of selenium will result in a higher tissue selenium concentration than
intake in the selenocysteine fonn (96).
Intake of selenium in the selenocysteine form will affect only the selenocysteine
compartment. Since this compartment is .regulated, it may be used to determine selenium
deficiency. Once the selenium requirement is met, it may not be used to determine
selenium status (96).
The relationship between selenium and cancer has been under scrutiny for many
years. Interest increased when selenium was found to be necessary for the fonnation of the
antioxidant enzyme, glutathione peroxidac;;e (98). Most patients in case controlled studies
with cancer had lower blood concentrations of selenium than the controls (l09). This
could be misleading because cancer may decrease selenium status in a number of ways.
The cancer may sequester the selenium (110), cause reduced dietary intake and reduce or
alter nutrient absorption. As the disease advanced, the patients' blood selenium
concentrations continued to drop (111) and the more advanced the disease, the lower the
selenium concentration (112).
Willett et al found that average prediagnostic serum selenium values among cancer
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patients were significantly lower than matched controls (113). Other studies have been less
conclusive with both positive and negative results (109). There are many reasons for the
conflict in the various studies which include geographical factors (soil concentration
differences), dietary factors, and the relationship of selenium status with the concentraton
of other nutrients such as vitamin E. Larger studies with adequate variations in selenium
concentration and a sufficient number of specific cancers are needed to document further
the role of selenium and its effect on human cancer (109).
No studies were found on seleniwn excretion in relation to cisplatin chemotherapy.
However, selenium has been reported to decrease the nephrotoxicity of cisplatin when
given before the treatment cycle (5, 114).
The exact mechanism of action of selenium on cisplatin is not clear. An interaction
between selenium and the cisp,latin molecule which prevents reabsorption by renal cells but
does not impede antitumor activity has been hypothesized. This interaction may possihly
increase the benefits of cisplatin and reduce toxicity (114). Further study is needed to
determine the validity of such theories.
Manganese
A deficiency of manganese in animal nutrition was first recognized in mice and fall;
in 1931 (115). Manganese's role and possible deficiency in human nutrition was
established more recently (116).
Distribution of tissue concentrations of manganese throughout the human body
varies little from one individual to another (116). Manganese concentration is the highest in
the mitochondria; manganese also is found in pigmented areas such as the retina and
melanin granules. Tissues containing the highest concentrations of manganese are bone,
liver, pancreas, and kidney. Total body manganese is highest in the bone (up to 25%), due
to its mass. Dietary intake may influence bone manganese concentration.
Manganese functions as a component of metalloenzymes such as arginase,
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manganese superoxide dismutase and pyruvate carboxylase (116). Arginase is responsible
for urea fonnation. Rat studies have indicated that a manganese deficiency influences the
activity of arginase (116). Pyruvate carboxylase catalyzes the initial steps of carbohydrate
synthesis from pyruvate. Manganese deficiency lowers the activity of this enzyme but not
enough to actually inhibit gluconeogenesis (117).
Manganese superoxide dismutase activity which catalyzes 02- to H202 and 02 is
also reduced in the tissues of manganese deficient rats (118). Manganese acts as an
enzyme activator in various hydrolases, kinases, decarboxylases and transferases (119).
Two enzYmes which are specificially activated by manganese are the glycosyltransferases
and phosphoenolpyruvate carboxykinase (117). Several deficiency induced pathologies
and low activities of these enzymes were reported in manganese deficient animals (117).
Intestinal transport of manganese is not clearly understood. Perfusion studies have
indicated that intestinal absorption of manganese is possibly a rapid saturable process
which involves a high-affinity, low-capacity active-transport system (120). Manganese
enters the portal blood from the gastrointestinal tract and may associate with alpha2-
macroglobulin or remain free. It then travels to the liver where it is almost totally removed.
A small amount may enter the systemic circulation where it is oxidized to Mn3+ and bound
to transferrin (119).
Once manganese enters the liver, it is transported to five metabolic pools. One pool
represents the manganese which is taken up by lysosomes which then may be transferred to
the bile canaliculus. Biliary excretion may regulate manganese in this area; 50% of
intravenously injected manganese may be recovered in the feces within 24 hours.
Mitochondria have a capability for manganese uptake, and this is associated with the
second pool of manganese. The nuclear portion of the cell also contains a pool of
manganese; the role of manganese in this area has not been defined. A fourth pool of
manganese is included in the synthesis of newly fonned proteins (118). Manganese is
transported to and absorbed by extrahepatic tissues by a mechanism that has not been
33
identified. It is known that transferrin is the major manganese binding protein but it is not
known to what extent transferrin assists this uptake (121). The fifth pool of manganese is
free Mn2+. Fluctuations in the free manganese pool may regulate cellular metabolic control
similar to that of free Ca2+ and Mg2+ (118. 119).
Absorption of manganese is believed to occur throughout the small intestine.
Manganese absorption is relatively low and is not thought to be under homeostatic control
(119). Absorption of manganese in adults was reported to be from 2% to 15% using
manganese labeled test meals. Balance studies reported absorption to be greater than 25%
(122, 123).
Information regarding the effect of dietary components on manganese absorption is
limited. Animal studies have indicated a need to increase manganese when consuming high
amounts of calcium. phosphorus, fiber and phytate. This may be due to formation of
insoluble manganese complexes in the intestinal tract which reduces the amount of
manganese available for absorption. Iron also plays a role in manganese absorption.
Experimental animal and human studies indicated that manganese absorption increased in
the presence of iron deficiency; high dietary iron intake has been shown to cause a
manganese deficiency in some species. The mechanism responsible for this phenomena is
not clear (116).
Manganese deficiency has been observed in several animal species. These
symptoms include impaired growth and reproductive performance. skeletal abnormalities,
ataxia and complications in lipid and carbohydrate metabolism. Bone defects in the fonn
of shortened and thickened limbs, curvature of the spine and swollen and enlarged joints
due to manganese deficiency have been observed in most species (116). The probable
cause for these abnormalities in animals is the reduction of the activity of
glycosyltransferases secondary to manganese deficiency.
Another area where manganese deficiency has a profound effect is in pregnant
animals. These offspring have irreversible ataxia with lack of equilibrium and head
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retraction. Manganese deficient rats and guinea pigs also have been noted to have defects
in carbohydrate matabolism with abnonnal glucose tolerance (119).
Manganese deficiency also affects pancreatic function. Manganese deficient rats
may exhibit depressed pancreatic insulin synthesis and increased intracellular insulin
degradation (124). This effect of manganese deficiency on insulin production may be
secondary to the destruction of pancreatic beta cells (119).
Manganese deficiency affects pancreatic exocrine function. Manganese-deficient
rats showed an increase in pancreatic amylase content presumably due to a shift in amylase
synthesis or degradation (125).
Manganese deficiency may result in abnorrnallipid metabolism (116). Manganese
deficient animals were found to have high liver fat concentration. Manganese is believed to
playa role in steroid biosynthesis, and hypocholesterolemia has been observed in deficient
animals. Abnonnallipid metabolism was shown in deficient rats which were found to
have lower high-density-lipoprotein concentrations than controls (126). These rats also
exhibited a shift to smaller plasma HDL particles, lower HDL apolipoproteins (apo E)
concentrations and higher apolipoproteins C concentrations (126).
Research has indicated that a deficiency in manganese can lead to a number of
biochemical and structural defects in experimental animals. Manganese deficiency in
humans was first observed in 1972 (118). Friedman et at (127) studied a group of seven
young men fed manganese-deficient diets (0.11 mg Mnld) for 39 days. During this time,
all subjects exhibited negative manganese balance and five of the seven subjects developed
a fleeting dennatitis that disappeared once manganese status was restored. Serum calcium,
phosphorus and alkaline phosphatase concentrations increased consistently during the
depletion period which concurred with the suggestion previously made by Strause and
Saltman (128) that manganese deficiency may affect bone remodeling. Although
manganese deficiency has not been observed in humans consuming regular diets, there are
some diseases which have been linked to manganese irregularities. Some individuals with
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epilepsy have been found to have low blood manganese concentrations and children with
maple syrup urine disease and phenylketonuria have been reponed to have low tissue
manganese concentrations (129). Furthermore. manganese deficiency may be a possible
factor in the development of joint disease. hip abnormalities. congenital malfonnations and
osteoporosis (129). Despite these findings, evidence of manganese deficiency in the
general population is rare. Manganese toxicity in humans is a serious health hazard which
may result in severe neurologic and psychologic disorders (130). As a result, there is little
support for manganese supplementation of the typical diet.
Research regarding manganese levels in cancer patients has been scarce and
generally contradictory (131). Capel and associates studied trace elements including serum
manganese in patients with various tumors while they were receiving radiotherapy (7).
These patients' sera was monitored at four week intervals over a 5 month period and
compared with control patients from a healthy population. Blood samples were obtained
after an overnight fast. Results indicated no significant differences in the serum manganese
levels of the controls and the cancer patients (7). Previous studies had indicated higher
levels of manganese in breast tumors than in nonnal breast tissue (131). However. this
study and another report (6) concluded that such tissue increases were not enough to
influence serum levels.
Sullivan et al investigated the role of trace elements in various diseases and
concluded that evaluation of status becomes difticult because there are nutritional as well as
metabolic interactions among the different trace elements (6). Patients were studied only
after acute phases of disease or shock. Blood was drawn from the patient and control
group after an overnight fast. Serum manganese was studied using neutron activation
analysis. Serum from the group with malignancies was elevated slightly (0.011 ± OJ)11
uglml) compared to the control group (OJ){)6 ± 0.004 ~glml). The serum manganese was
more significantly elevated in those patients with arteriosclerotic congestive heart failure.
infection and psychoses when compared to the control group.
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It appears that levels of particular essential minerals are variable depending upon the
the individual's health status as well as the type of cancer or disease. Routine measurement
of trace mineral levels should be done in each individual patient so that proper
supplementation can be administered where necessary (7).
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CHAPTER III
METI-IODS
Study Population
This study was performed on a total of fourteen patients receiving cisplatin
chemotherapy for various types of malignant tumors. A description of the patient
population is given in table I. Other chemotherapeutic drugs listed (Table 1) are commonly
given in conjunction with cisplatin chemotherapy for additional antineoplastic therapy.
They are not known to cause nephrotoxic damage to the renal tubule. The first patient
entered into this study on September 22, 1993. The last patient entered on October 10,
1995. The amount of time that each patient remained on the study was dependent on the
number of chemotherapeutic cycles received. This varied from a minimum of 2 months to
a maximum of 6 months. This study was approved by the Institutional Review Board for
Protection of Human Subjects at Oklahoma State University, Stillwater, Oklahoma and the
Institutional Review Board and the Cancer Committee at St. John Medical Center, Tulsa,
Oklahoma. The patients were referred to the study by two oncologists. Details of the
study were explained to the patient and a patient information sheet was provided. A
consent form was signed and a copy was given to the patient.
Experimental Design
Twenty-four hour urine samples were collected and blood (for serum sampling)
was drawn prior to the initial chemotherapy, following the second cycle of chemotherapy,
and after all chemotherapy was completed. The time period that elapsed after completion of
chemotherapy before the last sample was drawn varied with some patients (Table I).
Table I: Patient Demographics
Patient Age Sex Tumor Body surface Total cisplatin dose Additional Serum/urine interval
Number arealm2 given! mg chemotherapeutic post treaunent
drugs given
I 51 Male Melanoma 1.81 405 carmustine 1 month
2 54 Male Lung 1.84 600 mutamycin!vinblastine 5 months
3 65 Female Ovarian 1.78 399 Taxol 1 month
4 65 Male Lung 1.85 540 etoposide/vincristine 1 month
5 45 Female Cervical 1.81 540 3 months
6 62 Female Ovarian 1.75 780 Taxol 4 months
7 73 Male Lung 2.0 470 etoposide/vincristine 4 months
8* 52 Female Lung 1.65 640 etoposide 31/2 months serum
5 months urine
9** 68 Male Lung 1.99 600 etoposide/vincristine 1month
10 79 Female Ovarian 1.68 751 Taxol 1 month
11 52 Male Lung 1.77 600 etoposide 2 months
14 58 Male Lung 2.15 200 etoposide 6 weeks
15 61 Female Lung 1.5 450 etoposide 2 months
16 61 Male Lung 1.75 360 etoposide 4 months
. .. 00 .0pIes cOllectea oeIOre 4tn aose or merapy
** Samples collected before 2nd dose of therapy
(,.,.,)
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Samples were drawn at the same time that routine lab work was being done for their
attending physician.
Experimental procedure
Cisplatin dosage for each patient was calculated according to body surface area and
protocol recommendations. The patients were also given intravenous infusion of saline and
mannitol with antiemetics prior to therapy.
Instructions were given to the patient by the lab technologist or a registered nurse
for the twenty four hour urine collection. The urine was collected in standard 24 hour urine
collection containers which were stored in plastic bags to limit trace mineral contamination.
The patient was instructed not to touch the top of the container or the urine funnel and to
keep the container and funnel covered at all times. The first void was to be discarded;
thereafter for the next 24 hours, all urine was to be collected in the urine container. After
the container was returned to the laboratory, an aliquot of urine from the 24 hour collection
was pipetted into a trace mineral free sample tuhe. The total 24 hour urine volume was
recorded. All urine samples were labelled and frozen immediately after collection.
Blood samples were drawn using 21G x 1 1/2" trace mineral free kur cone needles
into Sarstedt vacutainers containing gel and clot activator. The samples were centrifuged at
1500 to 2()()() revolutions per minute for ten minutes. Serum was removed willi plastic
pipettes and placed in trace mineral free tubes, labelled and frozen.
Serum samples were prepared for trace element concentration using a combination
of wet and dry ashing methods. Serum from each collection was pipetted into acid washed
borosilicate glass tubes. To these samples a half volume of concentrated nitric acid was
added and they were placed in an isotemp heating block at 85 degrees for 2 hours.
Hydrogen peroxide was added every two hours to each sample until they were completely
ashed and white in color (132). After ashing and evaporating to dryness, samples were
diluted with 0.5% nitric acid (double distilled, G. Fredrick Smith, Columbus OH). Time
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and amount of additions to each set of samples were recorded (132).
Serum samples analyzed for magnesium content were diluted with 0.5% nitric acid
containing 0.1 % lanthanum as chloride. Samples were then analyzed for serum
concentrations of magnesium, copper, zinc, iron and urinary concentrations of magnesium
and zinc by a Perkin-Elmer Model 5WOPe atomic absorption spectrophotometer using an
air acetylene flame at the most sensitive wave length for each element (133). Serum
concentrations of manganese and selenium and urinary concentrations of manganese and
iron were detennined using a HGA 600 graphite furnace and Zeeman background
correction(134). The same set of ashed samples were used for all serum analysis; urine
samples were not ashed prior to analysis.
Serum albumin, serum creatinine and urinary creatinine were analyzed using
standard methods on a Roche Fara clinical analyzer. Creatinine clearance was calculated
using 24 hour urinary creatinine fonnula: Milliliters of plasma cleared per minute per
d d rf Vcr x V 1.73 h U . f ...stan ar su ace area = p x~,w ere cr = concentratIOn 0 creatmme m
cr
urine; Per = concentration of creatinine in plasma in the same units as for urine; V=volume
of urine flow in m1 per minute; A=body surface area in square meters (135).
Statistical Methods
Data including means and standard errors of the mean were processed stasticially
using the PC SAS software. Changes in values over time were analyzed using a paired "t"
test Effects of higher dose versus lower doses were compared using the generalized linear
model (GLM) (136).
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CHAPTER IV
CISPLATIN CHEMOTHERAPY EFFECfS ON lRACE ELEMENT EXCRETION
AND SERUM CONCENTRATION
Mathis-Shildt K, Stoecker BI, Shildt RA.
Introduction
Cisplatin (cis-diamminechloroplatinum II) is an inorganic platinum compound that
has been used for over twenty years as a chemotherapeutic agent for several types of solid
tumors. It is used primarily in the treatment of lung, ovarian and head and neck carcinomas
(l). Severe nephrotoxicity is a major side effect of cisplatin use. This toxicity causes
tubular dysfunction which results in hypomagnesemia and hypokalemia (2). A cumulative
toxicity occurs to the glomeruli of the kidney leading to decreased glomerular filtration rate
(2).
The effect of kidney damage from cisplatin on trace element levels in serum and
excretion in urine is unclear. Renal excretion of iron and manganese with cisplatin
treatment has not been investigated. Sartori et al reported increased renal excretion of
magnesium (3). Sweeney et al reported increased urinary excretion of zinc in the urine
following cisplatin. The authors stated this increase did not reach significance due to small
sample size (4).
Serum levels of magnesium decrease with cisplatin use (3), whereas iron and zinc
levels have shown an increasing trend (4,5). Serum levels of copper have shown little
change with cisplatin chemotherapy (6).
This study was designed to examine the serum concentrations and total urine
excretion of selected trace elements in p.atients receiving cisplatin chemotherapy after two
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cycles and after the completion of therapy.
Methods
This study was performed on a total of fourteen patients receiving cisplatin
chemotherapy for various types of malignant tumors. Each patients' cisplatin dosage was
calculated according to body surface area and protocol. Patients were given intravenous
infusion of saline and mannitol with anti emetics prior to therapy. A consent fonn was
signed by each patient. This study was approved by the Institutional Review Board for
Human Subjects Research at Oklahoma State University, Stillwater, Oklahoma and the
Institutional Review Board and Cancer Committee at St. John Medical Center, Tulsa,
Oklahoma. A description of the patient population is given in table I (see Chapter 3).
Blood (for serum sampling) and twenty-four hour urine collections were collected
from each patient prior to initiation of chemotherapy; prior to their third cycle and at
completion of chemotherapy. The time period that elapsed after completion of
chemotherapy before the last sample was drawn varied with some pal\ents (tatYft. l~.
All blood and urine samples were collected in trace mineral free plasticware and
processed in acid washed glass. Serum samples were analyzed for magnesium, copper,
zinc, iron and urine samples for magnesium and zinc using a Perkin-Elmer Model 5100
PC atomic absorption spectrophotometer using an air acetylene flame. Serum
concentrations of manganese and selenium and urinary concentrations of manganese and
iron were analyzed by the graphite furnace with Zeeman background correction. Serum
albumin, serum creatinine and urine creatinine were analyzed using standard methods on a
Roche Fara clinical analyzer.
Data were processed statistically using the PC SAS software. Changes in values
over time were analyzed using a paired "t" test. Effects of higher dose cisplatin versus
lower dose were compared by using analysis of variance using the generalized linear model
(GLM) procedure.
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Results
Table I lists demographic data of the patient population including the total cisplatin
dose delivered to each patient and time interval that elapsed between the completion of
therapy and collection of blood and urine samples. Tables IT and ill summarize the serum
albumin, creatinine clearance and the mean serum concentration and urinary excretion of the
trace elements analyzed. These levels were measured prior to starting cisplatin therapy;
before the third cycle; and at various times after the completion of all therapy.
Serum albumin showed little change throughout the entire course of cisplatin
chemotherapy regardless of a change in weight. These patients were found to have a
significant weight loss from the beginning of the study to completion of chemotherapy
(p=O.OO20). (Data not shown). Serum magnesium concentrations dropped from the
baseline value of 608 ± 38 JlmollL to 508 ± 37 ~moUL (p=.002) after two cycles of
cisplatin. A tendency to decrease occurred in serum magnesium between baseline of 608 ±
38 J.UlloUL and the last level of 522 ±35 JlIT10llL (p<O.06). Serum zinc concentration
showed a tendency to increase from a baseline of 8.8 ± 0.5 ~mollL to 10.2 ± 0.4 ~mollL
after the second cycle (p<O.(l9). There was a significant decrease following the second
cycle from 10.2 ±0.4 ~mol/L to 8.8 ±0.4 ~mol/L after the final cycle (p<.O()9).
Serum copper concentrations changed only slightly and nonsigniticanlly from the
baseline of 23.7 ± 2.1 ~mollL to 22.9 ± 1.4 ~mol/L after the second cycle. After therapy
was completed, serum copper was 24.4 ± 2.0 ~mollL. Serum iron concentrations were
13.4 ± 2.2 ~mollL initially and 17.8 ± 2.6 ~molJL after the second cycle. Eight out of
fourteen patients had a higher serum iron concentration after the second cycle of therapy,
even though the increase was not significant. Nine patients had a higher serum iron values
after completion of therapy. Little change was noted in the serum selenium or manganese
before and after chemotherapy with cisplatin.
Creatinine clearance showed a decreasing trend from 105.6 ± 14.0 mmolJd to 80.5
±7.4 mmolld after the second cycle (p<0.117) to 57.7 ± 7.7 mmolJd after all therapy was
completed (p<O.OO6). Initial magnesium excretion in the urine was 1.92 ± .54 mmolld and
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2.00 ±.39 mmolld after the second cycle. After completion of therapy, the level was 2.2~
± .32 mmolld. Urinary zinc excretions were 10.8 ± 1.7 mmolld before therapy, 9.9± 2.2
mmol/d after the second cycle and 7.5 ±2.9 mmolld after the completion of all therapy.
This decrease was not showed significant Iron levels in the urine tended to decrease from
baseline of 0.75 ± .12 Ilmolld to 0.46 ± .05 ~molld after the second cycle of therapy
(p<0.06). At completion of therapy, urinary iron was 0.51 ± .09 Ilmolld (p=.12).
Urinary manganese was quite variable but showed no significant change throughout the
entire chemotherapeutic cycle.
Patients were grouped according to dose (those who received a total of 540 mg or
more of cisplatin versus those who received less then 530 mg for statistical analysis. Then:~
was a significantly greater decrease in creatinine clearance in the higher dose group (p=.02)
than the lower dose group. After two cycles of therapy, patients exposed to greater
amounts of cisplatin had slightly higher urinary magnesium concentrations compared to
those who were exposed to lesser amounts (p=.09). No significant increase or decrease of
the remaining trace elements in serum or urine was observed, based on total dosage.
Hematological parameters are outlined in Table IV. Hemoglobin values dropped
significantly from 127± 4 gIL to 111 ± 5 gIL (p=O.020) after the second cycle. This level
then declined to 100 ± 5 giL (p=O.OOO4) after completion of therapy. Hematocrit levels
decreased significantly from 0.38 ± 0.01 to 0.32 ± 0.01 (p<O.005) and then declined to
0.30 ±0.01 (p<O.OOOl). Leukocytes dropped significantly from 10.6 ± 1.02xH)9/L to 7.3
± 1.09 lOx9/L (p<O.OO4), then appeared to rise slightly at 8.7 ± 1.77x109/L. Platelets
showed a significant decrease from 404 ± 49x109/L at baseline to 289 ± 50x109/L
(p=.OO12) after therapy was completed.
Discussion
Cisplatin induced hypomagnesemia has been previously reported (3,6,7) apparently
as a result of significant impairment in proximal tubular resorption and distal tubular
function (2,8). OUf study showed a decrease in serum magnesium concentrations in
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fourteen patients between the serums obtained before therapy and the second sample that
was drawn after the second cycle of therapy. Magnesium levels then rose slightly after the
completion of cisplatin. Four out of the fourteen patients' serum magnesium levels
returned to or exceeded the baseline level I to 4 months after completion of therapy.
Magnesium excretion in the urine appeared higher than baseline after the second cycle in
50% of the fourteen patients and after completion of chemotherapy in 57% (8 patients).
This has been described in previous studies but followup was not as long as in our study
(3,6) Since cisplatin therapy results in hypomagnesemia, many oncologists supplement
their patients with magnesium during and after cisplatin chemotherapy. Patients in this
study were prescribed magnesium supplements of 1,000 to 3,O(X) mg per day based on
their serum magnesium levels. These supplements were prescribed throughout their
chemotherapeutic cycle and after completion of therapy which may explain the apparent
recovery of serum magnesium of patients on OUf study.
Previous studies have indicated that kidney impairment may last for days to months
after completion of therapy (2). The significant decrease seen in the creatinine clearance
after completion of therapy supports the acute and chronic renal damage. The continued
urinary loss of magnesium despite improving serum levels could indicate that luhular
function improves only slightly and that increased oral intake of magnesium is responsible
for higher serum and urine levels.
The effect of cisplatin chemotherapy on serum zinc concentrations is unclear. Our
study showed a tendency for increases in the serum zinc concentrations after the second
cycle when compared to the initital value. This agrees with Zumkely et aI, who found that
baseline serum zinc concentrations increased 48 hours following treatment. (6).
However, our study showed serum zinc levels return to baseline after the final
cycle of cisplatin. Urinary excretion of zinc in our study appeared to decrease in 50% of
the patients after completion of chemotherapy. Zumkley et al found decreasing urinary zinc
levels when baseline values were compared with levels taken three days after treatment with
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cisplatin (6). The reason for changes in zinc and urine zinc concentrations is unclear.
Other studies have indicated that cisplatin use may result in increased excretion of
the amino acids histidine and cysteine which have been shown to increase urinary zinc. It
has also been suggested that cisplatin may cause increased release of intracellular zinc due
to tumor lysis (4). These two studies would predict an increase rather than a decrease in
urine zinc concentrations might be expected. The mechanism for decreased urinary zinc
remains unexplained.
Previous studies indicated an increase in plasma iron levels following cisplatin
therapy (5,9). Our study showed levels in serum iron concentrations at baseline to be 13.4
± 2.2 ~oUL and 17.8 ± 2.6 ~moUL after the second cycle. Fifty-seven percent of the
fourteen patients had an increase in levels during this time. The final value was 17.1 ± 1.7
~mol/L with 64% of the patient population's serum iron levels increased. Explanations for
increased serum iron levels during cisplatin chemotherapy vary. The nephrotoxicity caused
by cisplatin may induce an erythropoietin deficiency resulting in decreased bone marrow
utilization of iron (10). Inhibition of erythropoiesis secondary to cisplatin therapy (11) or a
competitive displacement of iron from proteins in the plasma would also explain higher iron
levels (12).
Urinary iron excretion in our study appeared to decrease after the second course of
chemotherapy. No previous studies were found that investigated urinary iron excretion in
patients receiving cisplatin. Why urine iron excretions decreased is unclear. Creatinine
clearance also decreased during this time period; perhaps less iron was filtered thus causing
the subsequent tendency to increase in the serum iron concentrations and decreased urine
Iron.
Few data exist describing the effect of cisplatin on serum copper concentrations No
significant change in serum copper concentrations during cisplatin therapy was found in a
previous study (6). Our study also showed no significant change in serum copper or
manganese from baseline levels throughout the entire course of therapy.
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No prior studies were found on serum selenium concentrations in patients receiving
cisplatin chemotherapy. However, Berry et al (13) has suggested that selenium may reduce
the nephrotoxicity of cisplatin when given before the treatment cycle It is hypothesized that
a complex of cisplatin and selenium prevents reabsorption of cisplatin by renal cells. This
hypothesis has not been confirmed. Our study showed a very slight but insignificant
downward trend in serum selenium levels from baseline through the completion of therapy.
Further studies will be necessary to detennine if decreasing serum selenium levels increase
nephrotoxicity of cisplatin.
For further analysis, the patient population was divided into two groups: those
who received 540 mg of cisplain and above those who received 530 mg of cisplatin and
below. Our study showed a significant increase in creatinine clearance in the high dose
group (p=.02). There was no difference in renal metabolism of the trace element., in the
serum or the urine when looking at total dose exposure to cisplatin. It is unknown whether
higher doses of cisplatin would effect serum or urinary concentrations of trace elements.
Hematological parameters showed significant decreases in hemoglobin, hematocrit,
and leukocytes after the second cycle of therapy. Platelet count, hemoglohin and
hematocrit showed significant decreases after completion of therapy. This continns
previously described bone marrow suppression from cisplatin therapy in chronically ill
patients. If cisplatin causes erythropoietin deficiency as previously suggested (0), this
may also contribute to decreased red blood cell concentrations in these patients.
Conclusion
We conclude that cisplatin therapy causes a significant decrease in serum
magnesium concentrations after the second cycle. A decreasing trend in serum magnesium
concentrations after completion of therapy was found but was not significant. Serum
concentrations of zinc tended to increase slightly, then returned to baseline values after
completion of chemotherapy. Serum selenium, manganese, copper and iron concentrations
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showed no significant change throughout the entire course of therapy. Urinary
concentration of magnesium appeared to increase after completion of therapy. Total urinary
iron appeared to decrease after two cycles of therapy. Cisplatin has little effect on urinary
zinc or manganese concentration. Creatinine clearance showed a significant decrease
throughout the entire cisplatin treatment
A significant decline occurred in hemoglobin and hematocrit levels following the
second cycle and completion of therapy. Leukocytes declined significantly following the
second cycle and platelets showed a significant drop in levels after completion of
chemotherapy.
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Table II • Serum concentrations of albumin and selected trace elements at indicated times in relation to cisplatin
chemotherapy
(1) (2) (3) P Value
Before therapy After 2nd cycle After final cycle 1 v 2 I v 3
Albumin (gIL) 43.7 ± 2.99 51.2±29 48.3 ± 2.45
(14) (14) (14)
Magnesium ij.lmolJL) 608 ± 38 508 ± 37 522 ± 35 p=0.002 p<0.06
(14) (14) (14)
Zinc (~olJL) 8.8 ± 0.5 10.2 ± 0.4 8.8 ± 0.4 p<0.09 p=0.009
(12) (12) (12) (2 v 3)
Copper (~oVL) 23.7 ± 2.1 22.9 ± 1.4 24.4 ± 2.0 P<0.70 p<0.72
(14) (14) (14)
Iron (~ollL) 13.4 ± 2.2 17.8 ± 2.6 17.1 ± 1.7 p<0.23 p<O.23
(14) (14) (14)
Selenium (nmolJL) 1734±213 1633 ± 131 1585 ± 298 p<0.58 p<0.71
(I 1) (11) (11)
Manganese (nmol/L) 176.2±21.1 162.4 ± 14.2 194.6 ± 28.6 p<O.50 p<O.61
(12) (12) (12)
~. 6. ..J.&""l:L.A,.,,*,;,,~ -J.-
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Table III: Urinary creatinine clearance and urine excretion of selected trace elements at indicated times in relation
to cisplatin chemotherapy
(1) (2) (3) P Value
Before therapy After second cycle After final cycle 1 v 2 1 v 3
Creatinine Clearance 105.6 ± 14.0 80.5 ± 7.4 57.7 ± 7.77 p<0.117 p<0.006
(mmoVd) (14) (13) (14)
Magnesium (mmolfd) 1.92 ±.54 2.00 ± .39 2.23 ± .32 p<O p<0.60
(14) (13) (14)
Zinc (mmolfd) 10.8 ± 1.7 9.9 ± 2.2 7.5 ± 2.9 p<0.60 p<0.27
(14) (13) (14)
Iron (JlffioVd) 0.75 ± 0.12 0.46 ± 0.05 0.51 ± 0.09 p<0.06 p=0.12
(14) (13) (14)
Manganese (nmol/d) 1.43 ± .384 1.36 ± .497 2.81 ± 1.32 p<0.73 p<0.26
(14) (13) (14)
VI
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Table IV - Hematological parameters at indicated times in relation to cisplatin chemotherapy
(1) (2) (3) P Values
Before therapy After 2nd cycle After final cycle I v 2 1 v 3
Hemoglobin (giL) 127 ± III ± 5 lOO± 5 p= 0.020 p=0.OO04
(14) (14) (14)
Hematocrit (1) 0.38 ± 0.01 0.32 ± 0.01 0.30 ± 0.01 p<0.005 p=O.OOOI
(14) (15) (15)
Leukocytes 109/L 10.6 ± 1.02 7.3 ± 1.09 8.7 ± 1.77 p<0.004 p<O.28(14) (14) (14)
Platelets 109/L 404. ± 49.1 353 ± 51.6 289 ± 50.1 p<0.21 p=0.OOI2(14) (14) (13)
VI
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CHAPTER 5
Summary
The effect of cisplatin chemotherapy on trace elements in serum and their excretion
in urine was studied in fourteen patients receiving cisplatin for various types of malignant
twnors. Urine samples were collected and blood samples were drawn from each patient
prior to beginning chemotherapy; after the second cycle and at various times after
completion of therapy. Serum concentrations of magnesium, zinc, copper, iron, selenium
and manganese were investigated. Urinary concentrations of magnesium, zinc, iron and
manganese were also measured.
Conclusions
We conclude that cisplatin therapy causes a significant decrease in serum
magnesium concentrations after the second cycle as well as a decreasing, hut non-
significant, trend in serum magnesium concentrations after completion of therapy. Serum
concentrations of zinc appeared to increase slightly, then returned to baseline values after
completion of chemotherapy. Selenium, manganese, copper and iron serum concentrations
showed no significant change throughout the entire course of therapy. Urinary
concentration of magnesium appears to increase after completion of therapy. Total urinary
iron appeared to decrease after two cycles of therapy. Cisplatin has little effect on urinary
zinc or manganese concentration. Creatinine clearance shows a signiticant decrease
throughout the entire cisplatin treatment.
A significant decline occurred in hemoglobin and hematocrit levels following the
second cycle and completion of therapy. Leukocytes declined significantly following the
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second cycle and platelets showed a significant drop in levels after completion of
chemotherapy.
Recommendations
The following recommendations for future research were developed from this study:
I) Final sample collection should be done at the same time interval for all patients.
i.e, last urine collection and blood draw should be done one month afler
completion of chemotherapy for all participating patients. Too much time
variation between last sample collection intervals makes it difficult to draw any
conclusions regarding those levels.
2) Increase number of patients on the study if clinically possible. Too small
patient population reduces chances for significance.
3) Increase amount of serum collected for analysis. Some serum samples were not
available for analysis (selenium) due to shortage of serum.
4) Consider erythropoietin analysis to help reach conclusions.
.,
,
,
'.
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CONSENT FORtvI
r. . hereby give consent for my participation in the
project entitled. "The Effects of Cisplatin/Carboplatin Based Chemotherapy on
Trace Element Excretion". The research for this project will take place at
intervals during the entire length of my chemotherapy. I authorize
LaFortune Cancer Center to perform the following treatment or procedures:
1. I understand that my physician requires a blood sample to analyze kidney
function at routine intervals throughout my Cisplatin therapy. [agree to
alJow an additional 10 ccs of blood to be collected during these times to be used
in the research of this study.
2. I understand that I will be asked to provide a 24 hour urine collection
sample in addition to the routine blood samples at the beginning, prior to the
third chemotherapy treatment, and at the end of my entire treatment cycle.
This urine sample will be specifically for the research project. l also
understand that I will be provided with a collection container at no charge to
me or my insura.nce company.
3. I understand that I will be asked to fill out a Food Frequency Questionnaire
prior to beginning my chemotherapy and at the end of the treatment cycle.
4. I understand that should I decide to start taking any type of vitamin
supplementation during my treatment cycle. I will notify Lafortune Cancer
Center the brand name and dosage amount of the supplement or supplements.
5. I understand that test results from my medical chart related to kidney
function and to nutritional status will be analyzed as part of this research
project.
6. I understand that all data obrained will become a part of my medical chart
and therefore will be confidential information. Specimens collected will be
classified according to number so that I am assured of confidentiality
7. I understand that this study will not interfere with my medical treatment in
any way.
8. I understand that the purpose of this study is to investigate the effect of
cisplatin/carboplatin based chemotherapy on the kidney's ability to maintain
proper trace mineral status.
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9. 1 understand that this participation is voluntary and that the information
that I provide will be kept confidential. 1 understand that I may refuse to
participate in this research and may withdraw from this study at any time for
any reason without prejudice.
l may contact LaFortune Cancer Center (918) 7-1-4-3180 should I wish further
information about this research. I also may contact Barbara Stoecker, Ph.D..
R.D .. L.D., l'iutritional Sciences, .+25 RES, Oklahoma State University, Stillwater.
OK, phone (405) 744-5040 and/or Seth :vrcTeman Stillwater, OK 74078. phone
(405) 744-5700.
If I should wish to contact an individual at St. John ivledical Center regarding
my rights as an individual in this research protocol. [ may contact Antonio C.
de Leon. Jr.. M.D., Chairman of the Institutional Review Board at (918) 744-2875.
I have read and fully understand the consent form. [sign it freely and
voluntarily. A copy has been given to me.
Signed. ....-J.JDate _
I have discussed this research with the participant (and/or his or her
authorized representative) using language which is understandable and
appropriate. I acknowledge that the nature and purpose of this
investigational research has been explained to the patient. There are no risks
or pOSSibility of complications involved in conjunction with this study. All of
the above has been explained co the patient or his representative by me
before the patient consented. I have explained ro the patient that he/she may
withdraw from this study at any time for any reason without prejudice.
Signed. _
(Project director or authorized representative)
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PATIENT INFORlvlATION (Cisplatin)
Cisplatin is a potene anticancer drug used for your type of cancer but there are
some things that we do not know about this drug. One question is what effect
the drug has on the trace minerals in your body.
We would like to ask your help with a research project to Learn more about the
effects of cisplatin on trace minerals, (specifically iron. magnesium,
manganese, selenium, copper and zinc) so that recommendations can be made
about the trace mineral needs of patients receiving cisplatin.
Your physician will be ordering routine lab work from time to time
throughout your therapy. We ask that you allow us [Q draw an additional IOces
(which is equal to two teaspoons) of blood at three of these times to use for this
project--before you begin your first cycle. before your third cycle and after
the final or sixth cycle of treat:ment, whichever comes first. Since this extra
blood will be drav.n with the same needle as your routine lab work, there will
be no additional needle sticks involved. If you participate in this study, you
will be asked [Q provide us with a 24 hour urine sample prior to beginning
your therapy, before your third cycle of therapy and after the sixth or final
cycle of your chemotherapy. In addition. we will ask you to fill out a
nutritional questionnaire before you begin your chemotherapy and after you
have finished taking ali of your chemotherapy rreannent. This will help us
determine how diet mayor may not playa role in the loss of these minerals.
This study would not interfere in any way with your therapy and has the
approval of your physician. You are not required to participate in this project
and you could disconeinue the study at any time.
There would be no charge to you for these additional studies and the results of
these studies will be added [Q your medical records. These analyses may be of
help to your physician in prOViding your medical care. If you are interested
in being a participant in this project we will prOVide you with a copy of the
consenl: form, show you the amount of additional blood needed for the tests and
answer any questions you may have about this research.
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~ ~ 51. JOHN MEDICAL CENTER
'J Medical Excellence. Compassionate Care
November 24, 1992
Kitty Mathis-Shildt, P.L.D.
224 Sunset Drive
Tulsa, OK 74114
Re: "The Effects of Cisplatin-Carboplatin Based
Chemotherapy on Trace Element Excretion"
Oe~r Mrs. Shildt:
At the Research Committee of November 9th, the Cancer Committee
of November 13th, as well as the Institutional Review Board of
November 24th, members reviewed and approved the above referenced
protocol and consent form.
You will be requested to provide update reports concerning your
patient'S experience on this protocol on a twice yearly basis.
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